Aayush Wellness shares climbed nearly 7% on Wednesday following a 10.6% increase in consolidated income for the first half of FY27. While revenue growth drew investor attention, the company faces margin pressure, as profit growth trailed behind sales. Investors are now monitoring the high reliance on non-operating income and rising inventory levels which have impacted cash flow.
Aayush Wellness Ltd shares recorded an intraday gain of approximately 7% on Wednesday, closing around Rs 26.55. The stock movement followed the release of the company’s financial results for the first half of the 2027 fiscal year, which showed a steady increase in top-line revenue alongside challenges in profitability.
For the six months ending September 30, 2026, the company reported a consolidated income of Rs 70.62 crore, a 10.61% increase compared to the same period last year. Profit after tax also moved upward, reaching Rs 2.50 crore, which represents a 5.86% growth year-on-year. While the revenue figures indicate market traction, the slower pace of profit growth compared to income suggests that rising input costs are putting pressure on the company's operating margins.
One significant point for investors is the composition of the company’s profits. A deeper look at the financials reveals that more than 50% of the profit before tax in the first half of the year was derived from 'other income' rather than core business operations. This dependency on non-operating sources is a key factor to track, as it raises questions about the sustainability of profitability solely through the company’s healthcare and nutraceutical business.
In terms of operations, Aayush Wellness continues to pivot toward specialized health segments. The company recently expanded its product catalog by launching bone and joint health solutions in October 2026, following earlier introductions of metabolic wellness and lung care products. While this expansion is aimed at capturing consumer demand in the growing nutraceutical market, it has also led to increased working capital requirements.
The company is currently experiencing negative cash flow from operating activities, primarily due to an increase in inventories and current assets. This build-up suggests that while the company is aggressively scaling its distribution and product pipeline, it is simultaneously consuming cash to maintain these inventory levels.
Looking ahead, market participants will monitor whether the company can translate its revenue growth into better core operating margins. The primary monitorables for shareholders include the company's ability to reduce its reliance on non-operating income, manage its working capital more efficiently, and stabilize cash flows as it continues its push into the competitive preventive healthcare space.